The safety of LYFGENIA™ was evaluated in 45 patients with a median (min, max) duration of follow-up of 42 (12, 87) months1

Adverse Reactions ≥Grade 3 (>5%) Following Treatment With LYFGENIA from Day 1 to Month 24 (N=45)1*

Adverse Reaction Grade 3 or higher n (%)
Blood and lymphatic system disorders
Thrombocytopenia 31 (69)
Neutropenia 27 (60)
Febrile neutropenia 20 (44)
Anemiaa 15 (33)
Leukopenia 15 (33)
Sickle cell anemia with crisisb 7 (16)
Gastrointestinal disorders
Stomatitis 32 (71)
Nausea 4 (9)
General disorders and administration site conditions
Pyrexia 3 (7)
Infections and infestations
Bacteremia 3 (7)
Investigations
Aspartate aminotransferase increased 8 (18)
Alanine aminotransferase increased 6 (13)
Gamma-glutamyl transferase increased 6 (13)
Blood bilirubin increased 3 (7)
Metabolism and nutrition disorders
Decreased appetite 5 (11)
Respiratory, thoracic, and mediastinal disorders
Pharyngeal inflammation 5 (11)

aIncludes a patient with α-thalassemia trait (-α3.7/-α3.7) who was diagnosed with myelodysplastic syndrome after Month 24.1

bIncludes events prior to Month 6 and non-adjudicated occurrences.1

*Includes adverse events associated with busulfan myeloablative conditioning and underlying sickle cell disease.1

Back
to Top

Additional Safety Data

  • Three patients died during LYFGENIA clinical trials1;
    • 1 from sudden cardiac death due to underlying disease and1
    • 2 from acute myeloid leukemia who were treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A)1
  • 33 (73%, 33/45) patients who received LYFGENIA experienced at least 1 serious adverse event (SAE). Most SAEs were related to conditioning or underlying disease1
  • Mobilization and apheresis triggered SAEs of sickle cell crisis in 6 (14%, 6/44) patients who initiated mobilization in the intent-to-treat population1
  • All patients who initiated conditioning (100%, 45/45) experienced at least 1 adverse event attributed to conditioning. The majority of conditioning-attributed events were non-serious and were consistent with the known effects of alkylating agents1
  • Pre-medication for infusion reactions was managed at physician discretion. Infusion-related reactions to LYFGENIA were observed in 2 patients on the day of LYFGENIA infusion. Both infusion-related reactions resolved and were Grade 1. Events included hot flush and decreased diastolic blood pressure1

Additional Safety Considerations

Hematologic Malignancy1 Open Close

Hematologic malignancy has occurred in patients treated with LYFGENIA (Study 1, Group A).

  • At the time of initial product approval, two patients treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A) developed acute myeloid leukemia (AML)
  • One patient with α-thalassemia trait (-α3.7/-α3.7) (Study 1, Group C) has been diagnosed with myelodysplastic syndrome (MDS)
  • The additional hematopoietic stress associated with mobilization, conditioning, and infusion of LYFGENIA, including the need to regenerate the hematopoietic system, may increase the risk of a hematologic malignancy
  • Patients with sickle cell disease have an increased risk of hematologic malignancy as compared to the general population
  • Patients treated with LYFGENIA may develop hematologic malignancies and should have lifelong monitoring
  • Monitor for hematologic malignancies with a complete blood count (with differential) at least every 6 months for at least 15 years after treatment with LYFGENIA, and integration site analysis at Months 6, 12, and as warranted
  • There is a potential risk of lentiviral vector–mediated insertional oncogenesis after treatment with LYFGENIA.
  • There are no data on the effects of LYFGENIA on fertility. Data are available on the risk of infertility with myeloablative conditioning. Advise patients of the risks and options for fertility preservation
  • Two patients developed anemia following LYFGENIA treatment; one patient continues to require monthly packed red blood cell (pRBC) transfusions. The other patient has been diagnosed with MDS. Both subjects had α-thalassemia trait (-α3.7/-α3.7)

All patients achieved neutrophil engraftment, with the reported median (min, max) day being Day 20 (12, 35) after LYFGENIA infusion

  • There is a potential risk of neutrophil engraftment failure. Monitor neutrophil counts until engraftment has been achieved. If neutrophil engraftment failure occurs, provide rescue treatment with the back-up collection of CD34+ cells

Neutrophil engraftment was defined in clinical trials as having 3 consecutive ANC laboratory values ≥0.5 × 109 cells/L obtained on 3 different days by Day 43

  • Platelet engraftment was achieved in all patients with a reported median (min, max) day of Day 37 (19, 235) after LYFGENIA infusion
  • Two patients treated with LYFGENIA achieved platelet engraftment after Day 100; one of these patients was administered eltrombopag until Day 234
  • Delayed platelet engraftment has been observed with LYFGENIA. Bleeding risk is increased prior to platelet engraftment and may continue after engraftment in patients with prolonged thrombocytopenia
  • Monitor patients for thrombocytopenia and bleeding

Platelet engraftment was defined in clinical trials as having 3 consecutive platelet values ≥50 × 109/L obtained on different days after the initial post-transplant nadir without receiving any platelet transfusions for 7 days immediately preceding and during the evaluation period

As LYFGENIA is an autologous therapy, prophylactic long-term immunosuppressive agents were not required in clinical studies. There were no cases of graft failure or graft rejection

Explore more about LYFGENIA

Clinical Results
Treatment Process

Sign up here to receive emails with more LYFGENIA information and resources

Sign up here to receive emails with more LYFGENIA information and resources